There are currently 37 clinical trials in Kingwood, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Lumi Research and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Texas Cardiology Research Center, Kingwood, Texas
Conditions: Acute Coronary Syndrome
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Texas Cardiology Research Center, Kingwood, Texas
Conditions: Atrial Fibrillation
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an... Read More
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
03/25/2024
Locations: Millennium Research & Clinical Development /ID# 228284, Kingwood, Texas
Conditions: Diffuse Large B-Cell Lymphoma
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Recruiting
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/22/2024
Locations: Research Site, Kingwood, Texas
Conditions: Asthma
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Lumi Research, Kingwood, Texas
Conditions: Non-small Cell Lung Cancer
MILDĀ® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Townsen Memorial Surgery Center-Kingwood, Kingwood, Texas
Conditions: Lumbar Spinal Stenosis
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Research Site, Kingwood, Texas
Conditions: Breast Cancer
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Recruiting
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/20/2024
Locations: Texas Cardiology Associates of Houston, Kingwood, Texas
Conditions: Atherosclerotic Cardiovascular Disease
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Research Site, Kingwood, Texas
Conditions: Breast Cancer
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Recruiting
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), n... Read More
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
03/19/2024
Locations: Texas Cardiology Assocs Of Houston ., Kingwood, Texas
Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Recruiting
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall... Read More
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Kingwood, Texas
Conditions: Prostate Cancer
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
Recruiting
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based survey... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Kingwood, Texas
Conditions: Asthma